Chikicha Editorial & Medical Disclaimer
This article is intended for education and public awareness and is based on scientific literature, peer-reviewed research, and recognized international authorities. The author is not a licensed medical doctor, psychiatrist, or healthcare professional, and this article does not constitute medical advice, diagnosis, or treatment. Readers should consult qualified healthcare professionals regarding individual health concerns or decisions. The author and Chikicha do not sell, endorse, or promote products, supplements, treatments, or medical interventions discussed in relation to this topic.
The Accelerators We Need to Recognize
In the first article, we established what sarcopenia is and why it cannot be understood simply as the loss of muscle mass. In the second, we moved inside the aging muscle and examined the biological processes that influence its ability to maintain, repair, and adapt. The aging muscle does not become biologically inactive; rather, several systems involved in maintaining it gradually become less efficient (Cruz-Jentoft et al., 2019; Kirk et al., 2024).
But biological aging is only part of the story, the muscle also ages within a body and a life that are constantly changing.
Periods of inactivity, illness, hospitalization, inadequate nutritional intake, chronic disease, metabolic dysfunction, and other conditions can place additional demands on a muscle that already has less physiological reserve than it once had. The scientific literature does not suggest that every one of these factors independently causes sarcopenia; rather, it shows that they can be associated with, contribute to, or intensify the conditions under which muscle loss and functional decline occur (Cruz-Jentoft et al., 2019).
Sarcopenia may develop gradually, but its trajectory can change when additional stressors converge, and understanding those stressors is the purpose of this article.
When the Muscle Stops Receiving the Signal
Skeletal muscle is highly responsive to mechanical loading. When that stimulus is substantially reduced, the muscle does not simply become less active; the biological processes that maintain its structure and function also begin to change. This makes prolonged inactivity or disuse an important accelerator to consider in the trajectory of sarcopenia. Casuso et al. (2024) examined this question through a systematic review and meta-regression of 51 human studies involving different models of muscle disuse, including bed rest and limb immobilization.
Across the studies, muscle disuse was associated with significant declines in both muscle mass and strength, but the reduction in strength was approximately twice as large as the reduction in muscle mass. The authors concluded that muscular strength and cardiovascular fitness decline to a greater extent than muscle mass during disuse, and their analysis suggested that neural factors may contribute substantially to the loss of strength. They also noted that disuse may have particularly serious consequences in older adults who already have low muscular strength (Casuso et al., 2024).
The biological explanation becomes clearer in more recent experimental evidence. Prokopidis et al. (2025) systematically reviewed and meta-analyzed studies using bed rest, unilateral lower-limb immobilization, and head-down tilt as models of muscle disuse. Their findings showed significant reductions in muscle protein synthesis following bed rest and in myofibrillar protein synthesis following unilateral limb immobilization. Their results indicate that when normal mechanical loading is removed, the muscle's capacity to maintain its protein balance is affected at a fundamental biological level (Prokopidis et al., 2025).
The consequences can also become visible in clinical settings. Aldrich et al. (2025), in a systematic review and meta-analysis of muscle changes during hospitalization, found that acute sarcopenia could develop within as little as four days in some patients. Across the studies included in their analysis, lower-limb rectus femoris muscle area decreased by approximately 16.5% over periods ranging from three to 21 days, while measures of muscle quality also declined. However, the pooled analysis did not demonstrate significant changes in handgrip or knee-extensor strength, leading the authors to caution that commonly used strength and functional measures may not always detect early changes in muscle health during hospitalization (Aldrich et al., 2025).
Altogether, these findings show why disuse is more than simply “not exercising.” Experimental evidence indicates that unloading can alter muscle protein synthesis and produce measurable losses in strength, mass, and physical capacity, while clinical evidence suggests that substantial changes in muscle tissue can occur during relatively short periods of hospitalization. The magnitude and expression of these changes differ according to the population, duration, type of disuse, and outcome being measured. For an aging muscle, this distinction matters, as aging may gradually reduce physiological reserve, but a period of substantial inactivity, immobilization, or illness can introduce an additional stressor at a time when the muscle may already have less capacity to compensate.
The accelerator is therefore not inactivity alone; it is the interaction between an aging muscle and the conditions that reduce the signals and resources it needs to maintain itself.
Image
When Decline Happens Faster
Ordinary reductions in activity are not the same as the profound inactivity that can occur during illness or hospitalization. Hospitalization creates a particularly important context because several stressors may occur simultaneously.
A person who becomes acutely ill may spend prolonged periods in bed, eat less than usual, experience inflammatory or metabolic stress, and temporarily lose the physical activities that normally stimulate muscle. Van Ancum et al. (2017), in a systematic review and meta-analysis of older hospitalized patients, examined changes in muscle strength and muscle mass during hospitalization and highlighted the vulnerability of older adults to muscle deterioration during this period.
More recent evidence has brought greater attention to what researchers describe as acute sarcopenia. Aldrich et al. (2025) reviewed 88 studies examining changes in muscle parameters during hospitalization and found a pooled incidence of acute sarcopenia of approximately 18% among the studies that reported incidence. The reported time required for development ranged from four to 44 days, although the populations, definitions, and methods differed considerably across studies. Importantly, the authors did not find a significant overall decline in handgrip or knee-extensor strength in their pooled analyses, illustrating why the effects of hospitalization should not be reduced to a single universal pattern.
What the research does establish is more nuanced: hospitalization can create a setting in which several pressures on muscle occur within a relatively short period. The extent of decline varies according to the individual and the circumstances, but the possibility of acute change helps explain why muscle vulnerability becomes particularly important during periods of illness.
When Several Stressors Arrive Together
The significance of hospitalization becomes clearer when the individual stressors are considered together. Illness may reduce movement, and reduced movement may diminish the stimulus normally supporting muscle maintenance. At the same time, appetite may change, nutritional intake may fall, and the physiological demands of illness may increase. These factors can overlap rather than occur independently, making it difficult to identify a single event responsible for the subsequent change in muscle.
This interaction is consistent with the broader framework established by EWGSOP2, which recognizes physical inactivity, disease, and inadequate energy or protein intake among the conditions associated with secondary sarcopenia (Cruz-Jentoft et al., 2019). The important point is not that every episode of illness produces sarcopenia, but that an aging muscle may have less reserve with which to absorb multiple simultaneous stresses. This is one reason the concept of an accelerator is useful, because it can change the conditions under which an already aging muscle must maintain itself.
When the Muscle Has Fewer Resources
Muscle maintenance also depends on adequate energy and nutrients, however, this does not mean that nutrition can be reduced to a single nutrient or that protein intake alone determines whether sarcopenia develops. Rather, nutritional status becomes particularly relevant when the body's requirements increase or intake becomes insufficient.
Prokopidis et al. (2025) examined the relationship between malnutrition and sarcopenia through a systematic review and meta-analysis. Their findings showed that malnutrition was associated with substantially greater odds of sarcopenia, while the coexistence of malnutrition and sarcopenia was also associated with poorer survival outcomes than sarcopenia alone. The authors' findings support the importance of nutritional status within the broader context of muscle health, while the observational nature and heterogeneity of the available studies limit conclusions about direct causation.
This distinction is important because the relationship between nutrition and muscle is not simply a matter of adding or removing one food from the diet. Adequate nutritional resources provide part of the environment in which muscle maintenance takes place, while inadequate nutritional status can become another pressure on that system. The effect may become particularly relevant when nutritional inadequacy occurs alongside illness, inactivity, or other sources of physiological stress.
When the Body Is Under Persistent Stress
Disease introduces another layer of complexity. EWGSOP2 distinguishes primary sarcopenia, associated principally with aging, from secondary sarcopenia, in which other conditions including disease, physical inactivity, and inadequate nutritional intake, may contribute (Cruz-Jentoft et al., 2019). This framework is useful because chronic diseases do not affect skeletal muscle through one universal pathway. Depending on the disease, changes in inflammation, metabolism, physical activity, nutritional status, organ function, or other physiological processes may coexist and influence muscle health.
Duarte et al. (2024), for example, examined sarcopenia among people with chronic kidney disease through a global systematic review and meta-analysis and found that sarcopenia was frequently observed in this population. Zuo et al. (2023) similarly found a higher prevalence of sarcopenia among populations with cardiovascular disease across the studies they reviewed. These findings demonstrate that sarcopenia frequently exists within the context of chronic disease, but they do not establish that either kidney or cardiovascular disease independently causes sarcopenia.
Therefore, chronic disease may create a biological and physical environment in which maintaining muscle becomes more difficult, but the pathway differs across conditions and individuals. Disease should therefore be understood as an important context for muscle vulnerability rather than as a single explanation for sarcopenia.
Image
When Muscle and Metabolism Move Together
The relationship becomes particularly interesting when we consider metabolic health. Skeletal muscle is one of the body's major metabolic tissues and plays an important role in glucose disposal and energy regulation. This creates a relationship that can operate in both directions: metabolic dysfunction can influence muscle, while changes in muscle quantity and quality can alter the body's metabolic capacity. The relationship is therefore more complex than simply describing muscle as an organ of movement.
Evidence among people with type 2 diabetes illustrates this interaction. Wu et al. (2026) synthesized 43 studies involving more than 19,000 Asian adults with type 2 diabetes and estimated a pooled sarcopenia prevalence of approximately 17%. Their analysis identified several factors associated with sarcopenia, including higher HbA1c, diabetic complications such as nephropathy and neuropathy, and higher body-fat percentage. Because many of the included studies were observational, these findings describe associations rather than proving that any single metabolic factor directly causes sarcopenia.
This is consistent with the broader biological picture from Article 2. Muscle and metabolism do not operate as separate systems; changes in one can alter the conditions in which the other functions. For an aging muscle, metabolic dysfunction can therefore become another component of an already changing biological environment.
When More Weight Does Not Mean More Functional Muscle
This relationship becomes even more visible in sarcopenic obesity, where excess adiposity and impaired muscle mass or function coexist. Donini et al. (2022), through the ESPEN and EASO consensus process, established a framework for defining and diagnosing sarcopenic obesity and emphasized the importance of considering both adiposity and muscle function rather than relying on body weight alone. Their consensus reflects an important shift in how body composition is interpreted: a larger body does not necessarily indicate greater muscular capacity.
The Asia-Oceania consensus subsequently developed a regional framework for the screening and diagnosis of sarcopenic obesity (Chen et al., 2025). Their work is particularly relevant to an aging Asian population in which obesity and declining muscle function may coexist. The authors' emphasis is not simply on body size, but on the relationship between adiposity, muscle quantity, and muscle function. Body weight, therefore, tells only part of the story. What matters as well is the condition of the tissue carrying that weight - and, ultimately, what that tissue is capable of producing.
When Inflammation and Catabolic Stress Intensify
Inflammation was already part of the biological landscape described in Article 2. In Article 3, the question is different: what happens when inflammatory or catabolic stress becomes more pronounced?
Acute illness, chronic disease, surgery, infection, and other physiological stresses can alter the balance of processes involved in tissue maintenance. When these stresses occur alongside reduced movement or inadequate nutritional intake, several pressures may act on the muscle simultaneously. The literature therefore increasingly considers inflammatory and catabolic processes as part of the interaction between illness and muscle decline rather than as isolated explanations.
The evidence does not support treating inflammation as a single switch that determines whether sarcopenia develops. Instead, it is better understood as one mechanism through which physiological stress can modify the environment in which muscle must maintain itself. This interpretation remains consistent with the systems perspective established in Article 2.
Medications: An Area That Requires Caution
Medication deserves attention because older adults are more likely to live with multiple chronic conditions and, consequently, multiple medications. But this is also an area where scientific caution is particularly important.
Prokopidis et al. (2023), in a systematic review and meta-analysis, found that sarcopenia was associated with a greater prevalence of polypharmacy and a higher number of medications. However, the authors explicitly noted that further research is needed to determine whether specific medications or medication burden directly contribute to muscle wasting and dysfunction. The association may also reflect the greater burden of underlying disease among people taking multiple medications.
Kuzuya (2024) subsequently discussed drug-related sarcopenia as a form of secondary sarcopenia, arguing that potential medication-related effects on skeletal muscle deserve greater attention. Yet this remains an area in which individual drugs, doses, underlying diseases, and patient characteristics matter. Medication use should therefore not be presented as a general cause of sarcopenia; the evidence supports a more careful question about when particular medications may contribute to muscular vulnerability. That distinction is important because responsible aging research requires us to recognize not only what has been observed, but also what has not yet been established.
Image
The Conditions Around Us Can Shape Movement
Muscle does not age independently of the environment in which a person lives. Opportunities for walking, access to recreational or exercise facilities, transportation, neighborhood safety, and other environmental characteristics can influence how easily older adults remain physically active.
Ferreira et al. (2025), in a systematic review examining the built environment and physical frailty and sarcopenia, identified associations between some environmental characteristics and these outcomes. At the same time, the authors emphasized that evidence specifically linking the built environment to sarcopenia remains limited and inconclusive, that limitation matters.
The environment should not be described as a proven direct cause of sarcopenia. Rather, it represents an emerging area of research concerning the conditions that may support or constrain opportunities for movement. For an aging population, the question extends beyond what an individual is willing or able to do to include the environments in which movement must occur.
The Compound Effect: When Accelerators Converge
The evidence across these different areas of research shows that the conditions affecting muscle often occur together, creating a sequence in which one stressor can make the next more consequential. Consider what can happen when an older person becomes ill.
Physical activity may decrease, hospitalization may follow, appetite may change, and nutritional intake may become inadequate, while inflammation and metabolic stress increase. Several days of reduced movement may then be followed by weakness, making movement even more difficult after discharge and potentially extending the period of recovery. Each event has its own explanation, but the resulting trajectory may be shaped by how these conditions interact over time.
This is consistent with the broader understanding of sarcopenia as a multidimensional process. The muscle is already undergoing age-related changes in protein turnover, neuromuscular function, mitochondrial activity, regeneration, inflammation, metabolism, and tissue composition. Additional stressors can occur on top of that biological background rather than replacing it (Cruz-Jentoft et al., 2019; Damanti et al., 2025).
The concept of acceleration therefore does not mean that one factor suddenly “causes” sarcopenia. It means that circumstances can place additional demands on a muscle whose biological reserve is already changing. The more those demands overlap, the more important the trajectory becomes.
Not Every Accelerator Is Permanent
These accelerators, however, do not necessarily determine the course of muscle decline. Some are temporary and the conditions surrounding them can change: an illness can resolve, hospitalization can end, physical activity can resume, nutritional status can improve, and rehabilitation can help restore function following a period of loss. This capacity for recovery is consistent with what we established in Article 2: aging muscle does not lose its ability to respond to appropriate stimuli, even though its responsiveness and physiological reserve may differ from those of younger muscle (Kristiansen et al., 2026).
The trajectory of muscle aging is therefore not fixed; periods of vulnerability can be followed by recovery, adaptation, and renewed capacity when the conditions supporting the muscle are restored. But this does not mean that every loss can be completely reversed, nor does the evidence justify promising that any particular intervention will prevent sarcopenia. It means something more modest and more useful: the trajectory of an aging muscle is influenced by the conditions surrounding it.
Recognizing those conditions gives us a reason to pay attention before a temporary stress becomes a lasting functional change.
The Trajectory Is Not Fixed
The evidence has taken us beyond the idea that sarcopenia is simply what happens when a person gets older. Aging creates a biological vulnerability: skeletal muscle changes, the systems that maintain it become less efficient, physiological reserve may narrow, and responsiveness to stimuli can change. Yet the aging muscle does not exist apart from the life surrounding it; its trajectory unfolds within patterns of movement and inactivity, periods of illness and recovery, nutritional circumstances, chronic and metabolic conditions, medication exposure, and the environments in which people live.
Some of these influences are unavoidable, some are temporary, and others may be modifiable, while for several, the evidence continues to evolve. What becomes clear across the research is that chronological age provides the context for muscle aging, but it does not fully explain how that aging is expressed from one person to another. What the research allows us to say with confidence is that the pace and expression of muscle decline are influenced by more than chronological age alone. The challenge is to understand those influences without exaggerating what science has established.
And this is where the evidence becomes personally meaningful. I cannot stop aging. None of us can.
But knowing that an aging muscle remains responsive, while also understanding that certain conditions can place additional pressure on it, changes the way I look at my own years ahead. I may not be able to prevent every decline, illness, or period of vulnerability, but I can become more attentive to the muscle I have, more conscious of the conditions that challenge it, and more deliberate about preserving, protecting, and strengthening the capacity I still possess.
Perhaps the deeper realization is that the goal was never to defeat aging. It is to give the body a better chance to travel through it with capacity. The evidence has shown me that muscle decline is not shaped by age alone; it unfolds through the interaction between biology and the circumstances of life. And if some of those circumstances can change, then perhaps what I can do is not control the destination, but influence the journey. If we now understand what can accelerate the decline, what can we do to slow it down?
And that question brings us naturally to the next part of our journey. In Article 4, let’s discover together what the evidence tells us about the muscle we can still build, preserve, and protect, and how those efforts can become part of life across the years.
The Muscle of Longevity: What Can We Do to Slow It Down?
Building and Protecting Muscle Across the Years
Image
Suggested Citation
Lendez, M.L. (2026). The Muscle Longevity: What Makes Sarcopenia Happen Faster. Chikicha.com (the author is the developer of the Ikigai-Bayanihan Framework for Purposeful Aging).
About the Author
Dr. Mariza Lendez is a researcher, social entrepreneur, and creator of the Ikigai-Bayanihan (Purpose + Collective Ethos) Retirement Model, an innovative framework that integrates purpose, community engagement, and sustainability to support meaningful aging and later-life well-being
References
Chen, T.-P., Kao, H.-H., Ogawa, W., Arai, H., Tahapary, D. L., Assantachai, P., Tham, K.-W., Chan, D.-C., Yuen, M. M.-A., Appannah, G., Fojas, M., Gill, T., Lee, M.-C., Saboo, B., Lin, C.-C., Kim, K.-K., & Lin, W.-Y. (2025). The Asia–Oceania consensus: Definitions and diagnostic criteria for sarcopenic obesity. Obesity Research & Clinical Practice, 19(3), 185–192. https://doi.org/10.1016/j.orcp.2025.05.001
Chien, S.-Y., Wang, T.-H., Tzeng, Y.-L., Lu, S.-H., & Chang, T.-S. (2025). Time allocation to physical activity and sedentary behaviour and its impact on sarcopenia risk: A systematic review and meta-analysis. Journal of Advanced Nursing, 81(10), 6250–6260. https://doi.org/10.1111/jan.16781
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinková, E., Vandewoude, M., Visser, M., & Zamboni, M. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31. https://doi.org/10.1093/ageing/afy169
Duarte, M. P., Almeida, L. S., Neri, S. G. R., Oliveira, J. S., Wilkinson, T. J., Ribeiro, H. S., & Lima, R. M. (2024). Prevalence of sarcopenia in patients with chronic kidney disease: A global systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 15(2), 501–512. https://doi.org/10.1002/jcsm.13425
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., Frara, S., Frühbeck, G., Genton, L., Gepner, Y., Giustina, A., Gonzalez, M. C., Han, H.-S., Heymsfield, S. B., Higashiguchi, T., … Barazzoni, R. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clinical Nutrition, 41(4), 990–1000. https://doi.org/10.1016/j.clnu.2021.11.014
Ferreira, L. dos S., da Silva, T. E. M., dos Santos, E. B., Fank, F., Barros Neto, J. A., & Menezes, E. C. (2025). The influence of the built environment and perceived neighborhood on physical frailty and sarcopenia in older adults: A systematic review. Archives of Gerontology and Geriatrics, 137, 105910. https://doi.org/10.1016/j.archger.2025.105910
Kuzuya, M. (2024). Drug-related sarcopenia as a secondary sarcopenia. Geriatrics & Gerontology International, 24(2), 195–203. https://doi.org/10.1111/ggi.14770
Prokopidis, K., Giannos, P., Reginster, J.-Y., Bruyère, O., Petrovic, M., Cherubini, A., Triantafyllidis, K. K., Kechagias, K. S., Dionyssiotis, Y., Cesari, M., Ibrahim, K., Scott, D., Barbagallo, M., & Veronese, N. (2023). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: A systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 14(2), 671–683. https://doi.org/10.1002/jcsm.13190
Prokopidis, K., Morgan, P. T., Deane, C. S., Witard, O. C., & Church, D. D. (2025). The effect of bed rest, unilateral limb immobilization and head-down tilt on muscle protein synthesis: A systematic review and meta-analysis. Experimental Physiology. https://doi.org/10.1113/EP092474
Prokopidis, K., Testa, G. D., Giannaki, C. D., Stavrinou, P., Kelaiditi, E., Hoogendijk, E. O., & Veronese, N. (2025). Prognostic and associative significance of malnutrition in sarcopenia: A systematic review and meta-analysis. Advances in Nutrition, 16(5), 100428. https://doi.org/10.1016/j.advnut.2025.100428
Sánchez-Sánchez, J. L., He, L., Morales, J. S., de Souto Barreto, P., Jiménez-Pavón, D., Carbonell-Baeza, A., Casas-Herrero, Á., Gallardo-Gómez, D., Lucia, A., del Pozo Cruz, B., & Valenzuela, P. L. (2024). Association of physical behaviours with sarcopenia in older adults: A systematic review and meta-analysis of observational studies. The Lancet Healthy Longevity, 5(2), e108–e119. https://doi.org/10.1016/S2666-7568(23)00241-6
Wu, Y.-C., Mao, M.-T., Huang, H.-E., Huang, C.-N., & Liao, W.-C. (2026). Prevalence and risk factors of sarcopenia in Asian adults with type 2 diabetes: A systematic review and meta-analysis. Journal of Diabetes Investigation, 17(1), 83–95. https://doi.org/10.1111/jdi.70185
Zuo, X., Li, X., Tang, K., Zhao, R., Wu, M., Wang, Y., & Li, T. (2023). Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 14(3), 1183–1198. https://doi.org/10.1002/jcsm.13221
Aldrich, L., Ispoglou, T., Prokopidis, K., Alqallaf, J., Wilson, O., & Stavropoulos-Kalinoglou, A. (2025). Acute sarcopenia: Systematic review and meta-analysis on its incidence and muscle parameter shifts during hospitalisation. Journal of Cachexia, Sarcopenia and Muscle, 16(1), e13662. https://doi.org/10.1002/jcsm.13662
Casuso, R. A., Huertas, J. R., & Aragón-Vela, J. (2024). The role of muscle disuse in muscular and cardiovascular fitness: A systematic review and meta-regression. European Journal of Sport Science, 24(6), 812–823. https://doi.org/10.1002/ejsc.12093
